

In the Claims

Claims 1-10 are pending in the present application. Claims 1-5 have been cancelled and claims 6-10 were previously presented.

Claims 1-5 (Canceled)

Claim 6. (Previously presented) A method of treating schizophrenia in a patient, the method comprising administering to the patient an effective amount of an antibody to tumor necrosis factor-alpha.

Claim 7. (Previously presented) The method of claim 6, wherein the antibody is selected from the group consisting of a polyclonal antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a monoclonal antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a humanized antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a synthetic antibody, a biologically active fragment thereof, an allelic variant thereof, a species variant thereof, a heavy chain antibody, and combinations thereof.

Claim 8. (Previously presented) The method of claim 6, wherein the antibody is administered by the route selected from the group consisting of intramuscularly, intravenously, intradermally, cutaneously, ionophoretically, topically, locally, and inhalation.

Claim 9. (Previously presented) The method of claim 6, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a synthetic antibody, a heavy chain antibody and a humanized antibody.

Claim 10. (Previously presented) The heavy chain antibody of claim 9, wherein the heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.